Azficel-T, an intradermal autologous fibroblast therapy, for the potential treatment of restrictive burn scars
3 may 2013
Fibrocell Science has begun a phase II trial of azficel-T, its intradermal autologous fibroblast therapy, for restrictive burn scars.
The double-blind, randomized, placebo-controlled study will assess the range of motion, brief pain index and scar appearance in 21 patients with burn scars. Primary efficacy and safety endpoints will be evaluated at 6 months.
David Pernock, Chairman and CEO of Fibrocell, said: “In addition to the aesthetic benefits of autologous fibroblasts, we are encouraged by their potential for the treatment of restrictive burn scarring. Patients have experienced the functional benefits of fibroblasts in individual case studies and we hope to confirm those benefits in the phase II trial”